 Treatment for AL amyloidosis aims to eradicate clonal plasma cells thereby disrupting the amyloid deposition causing organ damage . Risk adapted high dose melphalan plus autologous stem cell transplantation is an effective therapy . We conducted a prospective pilot analysis of a comprehensive approach using bortezomib and dexamethasone before and after RA ASCT in 19 patients . BD induction up to 3 cycles of bortezomib 1.3 mg m

@highlight We analyzed treatment with bortezomib and dexamethasone before and after risk adapted autologous stem cell transplantation.
@highlight This comprehensive 3 phase regimen is safe for the upfront management of AL amyloidosis.
@highlight We report deep including minimal residual disease negative durable remissions promoting organ recovery.
